



## Joachim Müller-Quernheim

### Contact

Joachim Müller-Quernheim

## Publications (3)

Boesing M, Abig K, Brändle M, Brutsche M, Burri E, Frye B, Giezendanner S, Grutters J, Haas P, Heisler J, Jaun F, Leuppi-Taegtmeier A, Lüthi-Corridori G, Müller-Quernheim J, Nüesch R, Pohl W, Rassouli F, Leuppi J. Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial. *Trials* 2022; 23:790.

Fischer A, Nöthen M, Herms S, Gieger C, Strauch K, Winkelmann J, Boehm B, Brand S, Büning C, Schürmann M, Ellinghaus E, Baurecht H, Lieb W, Nebel A, Müller-Quernheim J, Franke A, Schreiber S, Homolka J, Sterclova M, Ellinghaus D, Nutsua M, Hofmann S, Montgomery C, Iannuzzi M, Rybicki B, Petrek M, Mrazek F, Pabst S, Grohé C, Grunewald J, Ronninger M, Eklund A, Padyukov L, Mihailovic-Vucinic V, Jovanovic D. Identification of Immune-Relevant Factors Conferring Sarcoidosis Genetic Risk. *Am J Respir Crit Care Med* 2015; 192:727-36.

Baughman R, Barnathan E, Oemar B, Lo K, Flavin S, Schlenker-Herzeg R, Müller-Quernheim J, Donohue J, Davis G, Brutsche M, Albera C, du Bois R, Costabel U, Judson M, Kavuru M, Drent M, Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. *American journal of respiratory and critical care medicine* 2006; 174:795-802.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)